277 related articles for article (PubMed ID: 18606693)
1. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
Banerjee A; De M; Ali N
J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.
Asad M; Bhattacharya P; Banerjee A; Ali N
BMC Infect Dis; 2015 Apr; 15():188. PubMed ID: 25884796
[TBL] [Abstract][Full Text] [Related]
3. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.
Roychoudhury J; Sinha R; Ali N
PLoS One; 2011 Mar; 6(3):e17376. PubMed ID: 21423750
[TBL] [Abstract][Full Text] [Related]
4. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
5. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis.
Islamuddin M; Chouhan G; Want MY; Ozbak HA; Hemeg HA; Afrin F
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005011. PubMed ID: 27776125
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.
Pal S; Ravindran R; Ali N
Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135
[TBL] [Abstract][Full Text] [Related]
8. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
[TBL] [Abstract][Full Text] [Related]
11. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis.
Murray HW
J Immunol; 2005 Apr; 174(8):4916-23. PubMed ID: 15814719
[TBL] [Abstract][Full Text] [Related]
12. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
Sinha R; Roychoudhury J; Palit P; Ali N
Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
[TBL] [Abstract][Full Text] [Related]
13. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
[TBL] [Abstract][Full Text] [Related]
14. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
15. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.
Murray HW; Brooks EB; DeVecchio JL; Heinzel FP
Antimicrob Agents Chemother; 2003 Aug; 47(8):2513-7. PubMed ID: 12878513
[TBL] [Abstract][Full Text] [Related]
16. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
17. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.
Berman JD; Hanson WL; Chapman WL; Alving CR; Lopez-Berestein G
Antimicrob Agents Chemother; 1986 Dec; 30(6):847-51. PubMed ID: 3813512
[TBL] [Abstract][Full Text] [Related]
18. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.
Banerjee A; De M; Ali N
Antimicrob Agents Chemother; 2011 Apr; 55(4):1661-70. PubMed ID: 21220536
[TBL] [Abstract][Full Text] [Related]
20. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]